SMA Newsroom

Today, Novartis announced that the company has received the FDA approval for Itvisma® (onasemnogene abeparvovec-brve), the intrathecal formulation of onasemnogene abeparvovec, to treat SMA in adult and pediatric patients 2 years of age and older with a confirmed mutation in SMN1.

We’re thrilled to share the latest publication in SMA Europe’s One Goal editorial series!

Biogen announced that the high dose regimen of nusinersen received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). 

We are delighted to invite you to read the latest article on our Clinical Trials Finder website by SMA News Today.